Skip to main content
. 2020 Mar 18;156(5):1–8. doi: 10.1001/jamadermatol.2020.0290

Figure 1. Anti–Desmoglein (DSG) 1 and Anti-DSG3 Antibody Values During the 24-Month Period After Initial Treatment With Rituximab in Patients With Relapsing and Nonrelapsing Disease .

Figure 1.

ELISA indicates enzyme-linked immunosorbent assay; R, rituximab infusions; arrows, relapses; and error bars, SDs.